Jaguar Health Announces Strong Financial Growth in Q1 2026

Jaguar Health, Inc. (NASDAQ: JAGX) has reported a significant increase in net revenue by 816% in Q1 2026 compared to Q1 2025. This spike is largely attributed to the company’s strategic licensing agreement with Woodward Specialty, LLC, marking Woodward as the exclusive U.S. marketer for Mytesi and Canalevia-CA1 products. The move is expected to aid Jaguar’s ongoing focus on the development of crofelemer for addressing rare intestinal diseases.

Despite the rise in net revenue, totaling $20.3 million, the company recorded a net loss of $7.0 million attributed to common shareholders. However, this indicates an improvement from the $10.5 million loss in the same period the previous year. Additionally, Jaguar reported a significant decrease in sales and marketing expenses due to the dissolution of its sales group.

The company's operational income increased substantially by $19.6 million, transitioning from a loss to a positive $10.2 million, mainly due to license revenue and reduced operating expenses. Jaguar remains focused on its crofelemer powder fortification efforts as it continues to align its resources towards projects with lucrative prospects.